Avinger, Inc. announced that it has entered into a Securities Purchase Agreement with new investor, Zylox-Tonbridge Medical Technology Co., Ltd., pursuant to which the Purchaser agreed to purchase the shares of the Company?s common stock, par value $0.001 per share and shares of two new series of the Company?s preferred stock for the aggregate gross proceeds of $15,000,000 on March 4, 2024. The purchaser agreed to purchase in two tranches. Each share of Series F Preferred Stock has a stated value of $1,000 and is initially convertible into approximately 273 shares of Common Stock at a conversion price equal to the Purchase Price, subject to the terms of the Certificate of Designation of Preferences, Rights, and Limitations of the Series F Preferred Stock.
Zylox-Tonbridge Medical Technology Co., Ltd.
Equities
2190
CNE100004JD2
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.42 HKD | +0.77% | +6.87% | -16.24% |
Mar. 22 | Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 | MT |
Mar. 21 | Zylox-Tonbridge Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.24% | 433M | |
+12.07% | 128B | |
-9.04% | 10.65B | |
+0.91% | 8.82B | |
+16.72% | 7.19B | |
+25.15% | 4.99B | |
+7.17% | 3.4B | |
-1.36% | 3.03B | |
-8.73% | 2.14B | |
-10.15% | 2B |
- Stock Market
- Equities
- 2190 Stock
- News Zylox-Tonbridge Medical Technology Co., Ltd.
- Avinger, Inc. announced that it expects to receive $15 million in funding from Zylox-Tonbridge Medical Technology Co., Ltd.